I 
109TH CONGRESS 
2D SESSION 
H. R. 6247 
To amend the Public Health Service Act, the Employee Retirement Income 
Security Act of 1974, and the Internal Revenue Code of 1986 to require 
group and individual health insurance coverage and group health plans 
to provide coverage for individuals participating in approved cancer clin-
ical trials. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 28, 2006 
Ms. PRYCE of Ohio (for herself and Mrs. MYRICK) introduced the following 
bill; which was referred to the Committee on Energy and Commerce, and 
in addition to the Committees on Education and the Workforce and Ways 
and Means, for a period to be subsequently determined by the Speaker, 
in each case for consideration of such provisions as fall within the juris-
diction of the committee concerned 
A BILL 
To amend the Public Health Service Act, the Employee Re-
tirement Income Security Act of 1974, and the Internal 
Revenue Code of 1986 to require group and individual 
health insurance coverage and group health plans to 
provide coverage for individuals participating in approved 
cancer clinical trials. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Access to Cancer Clin-
ical Trials Act of 2006’’. 
SEC. 2. COVERAGE FOR INDIVIDUALS PARTICIPATING IN 
APPROVED CANCER CLINICAL TRIALS. 
(a) GROUP HEALTH PLANS.— 
(1) PUBLIC
HEALTH
SERVICE
ACT
AMEND-
MENTS.—Subpart 2 of part A of title XXVII of the 
Public Health Service Act is amended by adding at 
the end the following new section: 
‘‘SEC. 2707. COVERAGE FOR INDIVIDUALS PARTICIPATING 
IN APPROVED CANCER CLINICAL TRIALS. 
‘‘(a) COVERAGE.— 
‘‘(1) IN GENERAL.—If a group health plan (or 
a health insurance issuer offering health insurance 
coverage in connection with the plan) provides cov-
erage to a qualified individual (as defined in sub-
section (b)), the plan or issuer— 
‘‘(A) may not deny the individual partici-
pation in the clinical trial referred to in sub-
section (b)(2); 
‘‘(B) subject to subsection (c), may not 
deny (or limit or impose additional conditions 
on) the coverage of routine patient costs for 
items and services furnished in connection with 
participation in the trial; and 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(C) may not discriminate against the in-
dividual on the basis of the individual’s partici-
pation in such trial. 
‘‘(2) EXCLUSION OF CERTAIN COSTS.— 
‘‘(A) IN GENERAL.—For purposes of para-
graph (1)(B), subject to subparagraph (B), rou-
tine patient costs include all items and services 
provided in the clinical trial that are otherwise 
generally available to the qualified individual, 
except— 
‘‘(i) in the cases of drugs and devices, 
the investigational item or service, itself; or 
‘‘(ii) items and services that are pro-
vided solely to satisfy data collection and 
analysis needs and that are not used in the 
direct clinical management of the patient. 
‘‘(B) INCLUSIONS.—Such routine patient 
costs do include costs for the following: 
‘‘(i) CONVENTIONAL CARE.—Items or 
services that are typically provided absent 
a clinical trial. 
‘‘(ii) ADMINISTRATIVE ITEMS.—Items 
or services required solely for the provision 
of the investigational item or service (such 
as the administration of a noncovered 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
chemotherapeutic agent), the clinically ap-
propriate monitoring of the effects of the 
item or service, or the prevention of com-
plications. 
‘‘(iii) REASONABLE
AND
NECESSARY 
CARE.—Items or services needed for rea-
sonable and necessary care arising from 
the provision of an investigational item or 
service, including the diagnosis or treat-
ment of complications. 
‘‘(3) USE OF IN-NETWORK PROVIDERS.—If one 
or more participating providers is participating in a 
clinical trial, nothing in paragraph (1) shall be con-
strued as preventing a plan or issuer from requiring 
that a qualified individual participate in the trial 
through such a participating provider if the provider 
will accept the individual as a participant in the 
trial. 
‘‘(b) QUALIFIED INDIVIDUAL DEFINED.—For pur-
poses of subsection (a), the term ‘qualified individual’ 
means an individual who is a participant or beneficiary 
in a group health plan and who meets the following condi-
tions: 
‘‘(1)(A) The individual has been diagnosed with 
cancer. 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(B) The individual is eligible to participate in 
an approved clinical trial according to the trial pro-
tocol with respect to treatment of such illness. 
‘‘(2) Either— 
‘‘(A) the referring physician is a partici-
pating health care professional and has con-
cluded that the individual’s participation in 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1); or 
‘‘(B) the participant or beneficiary pro-
vides medical and scientific information estab-
lishing that the individual’s participation in 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1). 
‘‘(c) PAYMENT.— 
‘‘(1) IN GENERAL.—Under this section a group 
health plan (or health insurance issuer offering 
health insurance coverage in connection with the 
plan) shall provide for payment for routine patient 
costs described in subsection (a)(2) but is not re-
quired to pay for costs of items and services that are 
customarily provided by the research sponsors free 
of charge for individuals participating in the trial. 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(2) PAYMENT RATE.—In the case of covered 
items and services provided by— 
‘‘(A) a participating provider, the payment 
rate shall be at the agreed upon rate, or 
‘‘(B) a nonparticipating provider, the pay-
ment rate shall be at the rate the plan would 
normally pay for comparable items and services 
under subparagraph (A). 
‘‘(d) APPROVED CLINICAL TRIAL DEFINED.— 
‘‘(1) IN GENERAL.—In this section, the term 
‘approved clinical trial’ means a clinical research 
study or clinical investigation that relates to the 
treatment of cancer (including related symptoms) 
and is described in any of the following subpara-
graphs: 
‘‘(A) FEDERALLY FUNDED TRIALS.—The 
study or investigation is approved or funded 
(which may include funding through in-kind 
contributions) by one or more of the following: 
‘‘(i) NIH.—The National Institutes of 
Health. 
‘‘(ii) CDC.—The Centers for Disease 
Control and Prevention. 
‘‘(iii) AHRQ.—The Agency for Health 
Care Research and Quality. 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(iv) CMS.—The Centers for Medi-
care & Medicaid Services. 
‘‘(v) COOPERATIVE CENTER.—A coop-
erative group or center of any of the enti-
ties described in clauses (i) through (iv) or 
the Departments of Defense or Veterans 
Affairs. 
‘‘(vi) CENTER SUPPORT GRANTEES.— 
A qualified non-governmental research en-
tity identified in the guidelines issued by 
the National Institutes of Health for cen-
ter support grants. 
‘‘(vii) DOD; VA; DOE.—Any of the fol-
lowing if the conditions described in para-
graph (2) are met: 
‘‘(I) The Department of Veterans 
Affairs. 
‘‘(II) The Department of De-
fense. 
‘‘(III) The Department of En-
ergy. 
‘‘(B) FDA DRUG TRIAL UNDER IND.—The 
study or investigation is conducted under an in-
vestigational new drug application reviewed by 
the Food and Drug Administration. 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(C) EXEMPT DRUG TRIAL.—The study or 
investigation is a drug trial that is exempt from 
having such an investigational new drug appli-
cation. 
‘‘(2) CONDITIONS
FOR
DEPARTMENTS.—The 
conditions described in this paragraph, for a study 
or investigation conducted by a Department, are 
that the study or investigation has been reviewed 
and approved through a system of peer review that 
the Secretary determines— 
‘‘(A) to be comparable to the system of 
peer review of studies and investigations used 
by the National Institutes of Health, and 
‘‘(B) assures unbiased review of the high-
est scientific standards by qualified individuals 
who have no interest in the outcome of the re-
view. 
‘‘(e) CONSTRUCTION.—Nothing in this section shall 
be construed to limit a plan’s or issuer’s coverage with 
respect to clinical trials.’’. 
(2) ERISA AMENDMENTS.—(A) Subpart B of 
part 7 of subtitle B of title I of the Employee Re-
tirement Income Security Act of 1974 is amended by 
adding at the end the following new section: 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘SEC. 714. COVERAGE FOR INDIVIDUALS PARTICIPATING IN 
APPROVED CANCER CLINICAL TRIALS. 
‘‘(a) COVERAGE.— 
‘‘(1) IN GENERAL.—If a group health plan (or 
a health insurance issuer offering health insurance 
coverage in connection with the plan) provides cov-
erage to a qualified individual (as defined in sub-
section (b)), the plan or issuer— 
‘‘(A) may not deny the individual partici-
pation in the clinical trial referred to in sub-
section (b)(2); 
‘‘(B) subject to subsection (c), may not 
deny (or limit or impose additional conditions 
on) the coverage of routine patient costs for 
items and services furnished in connection with 
participation in the trial; and 
‘‘(C) may not discriminate against the in-
dividual on the basis of the individual’s partici-
pation in such trial. 
‘‘(2) EXCLUSION OF CERTAIN COSTS.— 
‘‘(A) IN GENERAL.—For purposes of para-
graph (1)(B), subject to subparagraph (B), rou-
tine patient costs include all items and services 
provided in the clinical trial that are otherwise 
generally available to the qualified individual, 
except— 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(i) in the cases of drugs and devices, 
the investigational item or service, itself; or 
‘‘(ii) items and services that are pro-
vided solely to satisfy data collection and 
analysis needs and that are not used in the 
direct clinical management of the patient. 
‘‘(B) EXCLUSION.—Such routine patient 
costs do include costs for the following: 
‘‘(i) CONVENTIONAL CARE.—Items or 
services that are typically provided absent 
a clinical trial. 
‘‘(ii) ADMINISTRATIVE ITEMS.—Items 
or services required solely for the provision 
of the investigational item or service (such 
as the administration of a noncovered 
chemotherapeutic agent), the clinically ap-
propriate monitoring of the effects of the 
item or service, or the prevention of com-
plications. 
‘‘(iii) REASONABLE
AND
NECESSARY 
CARE.—Items or services needed for rea-
sonable and necessary care arising from 
the provision of an investigational item or 
service, including the diagnosis or treat-
ment of complications. 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(3) USE OF IN-NETWORK PROVIDERS.—If one 
or more participating providers is participating in a 
clinical trial, nothing in paragraph (1) shall be con-
strued as preventing a plan or issuer from requiring 
that a qualified individual participate in the trial 
through such a participating provider if the provider 
will accept the individual as a participant in the 
trial. 
‘‘(b) QUALIFIED INDIVIDUAL DEFINED.—For pur-
poses of subsection (a), the term ‘qualified individual’ 
means an individual who is a participant or beneficiary 
in a group health plan and who meets the following condi-
tions: 
‘‘(1)(A) The individual has been diagnosed with 
cancer. 
‘‘(B) The individual is eligible to participate in 
an approved clinical trial according to the trial pro-
tocol with respect to treatment of such illness. 
‘‘(2) Either— 
‘‘(A) the referring physician is a partici-
pating health care professional and has con-
cluded that the individual’s participation in 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1); or 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(B) the participant or beneficiary pro-
vides medical and scientific information estab-
lishing that the individual’s participation in 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1). 
‘‘(c) PAYMENT.— 
‘‘(1) IN GENERAL.—Under this section a group 
health plan (or health insurance issuer offering 
health insurance coverage in connection with the 
plan) shall provide for payment for routine patient 
costs described in subsection (a)(2) but is not re-
quired to pay for costs of items and services that are 
customarily provided by the research sponsors free 
of charge for individuals participating in the trial. 
‘‘(2) PAYMENT RATE.—In the case of covered 
items and services provided by— 
‘‘(A) a participating provider, the payment 
rate shall be at the agreed upon rate, or 
‘‘(B) a nonparticipating provider, the pay-
ment rate shall be at the rate the plan would 
normally pay for comparable items and services 
under subparagraph (A). 
‘‘(d) APPROVED CLINICAL TRIAL DEFINED.— 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(1) IN GENERAL.—In this section, the term 
‘approved clinical trial’ means a clinical research 
study or clinical investigation that relates to the 
treatment of cancer (including related symptoms) 
and is described in any of the following subpara-
graphs: 
‘‘(A) FEDERALLY FUNDED TRIALS.—The 
study or investigation is approved or funded 
(which may include funding through in-kind 
contributions) by one or more of the following: 
‘‘(i) NIH.—The National Institutes of 
Health. 
‘‘(ii) CDC.—The Centers for Disease 
Control and Prevention. 
‘‘(iii) AHRQ.—The Agency for Health 
Care Research and Quality. 
‘‘(iv) CMS.—The Centers for Medi-
care & Medicaid Services. 
‘‘(v) COOPERATIVE CENTER.—A coop-
erative group or center of any of the enti-
ties described in clauses (i) through (iv) or 
the Departments of Defense or Veterans 
Affairs. 
‘‘(vi) CENTER SUPPORT GRANTEES.— 
A qualified non-governmental research en-
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
tity identified in the guidelines issued by 
the National Institutes of Health for cen-
ter support grants. 
‘‘(vii) DOD; VA; DOE.—Any of the fol-
lowing if the conditions described in para-
graph (2) are met: 
‘‘(I) The Department of Veterans 
Affairs. 
‘‘(II) The Department of De-
fense. 
‘‘(III) The Department of En-
ergy. 
‘‘(B) FDA DRUG TRIAL UNDER IND.—The 
study or investigation is conducted under an in-
vestigational new drug application reviewed by 
the Food and Drug Administration. 
‘‘(C) EXEMPT DRUG TRIAL.—The study or 
investigation is a drug trial that is exempt from 
having such an investigational new drug appli-
cation. 
‘‘(2) CONDITIONS
FOR
DEPARTMENTS.—The 
conditions described in this paragraph, for a study 
or investigation conducted by a Department, are 
that the study or investigation has been reviewed 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
and approved through a system of peer review that 
the Secretary determines— 
‘‘(A) to be comparable to the system of 
peer review of studies and investigations used 
by the National Institutes of Health, and 
‘‘(B) assures unbiased review of the high-
est scientific standards by qualified individuals 
who have no interest in the outcome of the re-
view. 
‘‘(e) CONSTRUCTION.—Nothing in this section shall 
be construed to limit a plan’s or issuer’s coverage with 
respect to clinical trials.’’. 
(B) Section 732(a) of such Act (29 U.S.C. 
1191a(a)) is amended by striking ‘‘section 711’’ and 
inserting ‘‘sections 711 and 714’’. 
(C) The table of contents in section 1 of such 
Act is amended by inserting after the item relating 
to section 713 the following new item: 
‘‘Sec. 714. Coverage for individuals participating in approved cancer clinical 
trials’’. 
(3) 
INTERNAL
REVENUE
CODE
AMEND-
MENTS.— 
(A) IN GENERAL.—Subchapter B of chap-
ter 100 of the Internal Revenue Code of 1986 
is amended— 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
(i) in the table of sections, by insert-
ing after the item relating to section 9812 
the following new item: 
‘‘Sec. 9813. Coverage for individuals participating in approved cancer clinical 
trials’’; and 
(ii) by inserting after section 9812 the 
following: 
‘‘SEC. 9813. COVERAGE FOR INDIVIDUALS PARTICIPATING 
IN APPROVED CANCER CLINICAL TRIALS. 
‘‘(a) COVERAGE.— 
‘‘(1) IN GENERAL.—If a group health plan pro-
vides coverage to a qualified individual (as defined in 
subsection (b)), the plan— 
‘‘(A) may not deny the individual partici-
pation in the clinical trial referred to in sub-
section (b)(2); 
‘‘(B) subject to subsection (c), may not 
deny (or limit or impose additional conditions 
on) the coverage of routine patient costs for 
items and services furnished in connection with 
participation in the trial; and 
‘‘(C) may not discriminate against the in-
dividual on the basis of the individual’s partici-
pation in such trial. 
‘‘(2) EXCLUSION OF CERTAIN COSTS.— 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(A) IN GENERAL.—For purposes of para-
graph (1)(B), subject to subparagraph (B), rou-
tine patient costs include all items and services 
provided in the clinical trial that are otherwise 
generally available to the qualified individual, 
except— 
‘‘(i) in the cases of drugs and devices, 
the investigational item or service, itself; or 
‘‘(ii) items and services that are pro-
vided solely to satisfy data collection and 
analysis needs and that are not used in the 
direct clinical management of the patient. 
‘‘(B) EXCLUSION.—Such routine patient 
costs do include costs for the following: 
‘‘(i) CONVENTIONAL CARE.—Items or 
services that are typically provided absent 
a clinical trial. 
‘‘(ii) ADMINISTRATIVE ITEMS.—Items 
or services required solely for the provision 
of the investigational item or service (such 
as the administration of a noncovered 
chemotherapeutic agent), the clinically ap-
propriate monitoring of the effects of the 
item or service, or the prevention of com-
plications. 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(iii) REASONABLE
AND
NECESSARY 
CARE.—Items or services needed for rea-
sonable and necessary care arising from 
the provision of an investigational item or 
service, including the diagnosis or treat-
ment of complications. 
‘‘(3) USE OF IN-NETWORK PROVIDERS.—If one 
or more participating providers is participating in a 
clinical trial, nothing in paragraph (1) shall be con-
strued as preventing a plan from requiring that a 
qualified individual participate in the trial through 
such a participating provider if the provider will ac-
cept the individual as a participant in the trial. 
‘‘(b) QUALIFIED INDIVIDUAL DEFINED.—For pur-
poses of subsection (a), the term ‘qualified individual’ 
means an individual who is a participant or beneficiary 
in a group health plan and who meets the following condi-
tions: 
‘‘(1)(A) The individual has been diagnosed with 
cancer. 
‘‘(B) The individual is eligible to participate in 
an approved clinical trial according to the trial pro-
tocol with respect to treatment of such illness. 
‘‘(2) Either— 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(A) the referring physician is a partici-
pating health care professional and has con-
cluded that the individual’s participation in 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1); or 
‘‘(B) the participant or beneficiary pro-
vides medical and scientific information estab-
lishing that the individual’s participation in 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1). 
‘‘(c) PAYMENT.— 
‘‘(1) IN GENERAL.—Under this section a group 
health plan shall provide for payment for routine pa-
tient costs described in subsection (a)(2) but is not 
required to pay for costs of items and services that 
are customarily provided by the research sponsors 
free of charge for individuals participating in the 
trial. 
‘‘(2) PAYMENT RATE.—In the case of covered 
items and services provided by— 
‘‘(A) a participating provider, the payment 
rate shall be at the agreed upon rate, or 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(B) a nonparticipating provider, the pay-
ment rate shall be at the rate the plan would 
normally pay for comparable items and services 
under subparagraph (A). 
‘‘(d) APPROVED CLINICAL TRIAL DEFINED.— 
‘‘(1) IN GENERAL.—In this section, the term 
‘approved clinical trial’ means a clinical research 
study or clinical investigation that relates to the 
treatment of cancer (including related symptoms) 
and is described in any of the following subpara-
graphs: 
‘‘(A) FEDERALLY FUNDED TRIALS.—The 
study or investigation is approved or funded 
(which may include funding through in-kind 
contributions) by one or more of the following: 
‘‘(i) NIH.—The National Institutes of 
Health. 
‘‘(ii) CDC.—The Centers for Disease 
Control and Prevention. 
‘‘(iii) AHRQ.—The Agency for Health 
Care Research and Quality. 
‘‘(iv) CMS.—The Centers for Medi-
care & Medicaid Services. 
‘‘(v) COOPERATIVE CENTER.—A coop-
erative group or center of any of the enti-
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
ties described in clauses (i) through (iv) or 
the Departments of Defense or Veterans 
Affairs. 
‘‘(vi) CENTER SUPPORT GRANTEES.— 
A qualified non-governmental research en-
tity identified in the guidelines issued by 
the National Institutes of Health for cen-
ter support grants. 
‘‘(vii) DOD; VA; DOE.—Any of the fol-
lowing if the conditions described in para-
graph (2) are met: 
‘‘(I) The Department of Veterans 
Affairs. 
‘‘(II) The Department of De-
fense. 
‘‘(III) The Department of En-
ergy. 
‘‘(B) FDA DRUG TRIAL UNDER IND.—The 
study or investigation is conducted under an in-
vestigational new drug application reviewed by 
the Food and Drug Administration. 
‘‘(C) EXEMPT DRUG TRIAL.—The study or 
investigation is a drug trial that is exempt from 
having such an investigational new drug appli-
cation. 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
‘‘(2) CONDITIONS
FOR
DEPARTMENTS.—The 
conditions described in this paragraph, for a study 
or investigation conducted by a Department, are 
that the study or investigation has been reviewed 
and approved through a system of peer review that 
the Secretary determines— 
‘‘(A) to be comparable to the system of 
peer review of studies and investigations used 
by the National Institutes of Health, and 
‘‘(B) assures unbiased review of the high-
est scientific standards by qualified individuals 
who have no interest in the outcome of the re-
view. 
‘‘(e) CONSTRUCTION.—Nothing in this section shall 
be construed to limit a plan’s coverage with respect to clin-
ical trials.’’. 
(B) CONFORMING
AMENDMENT.—Section 
4980D(d)(1) of such Code is amended by strik-
ing ‘‘section 9811’’ and inserting ‘‘sections 
9811 and 9813’’. 
(b) INDIVIDUAL HEALTH INSURANCE.—Part B of 
title XXVII of the Public Health Service Act is amended— 
(1) by redesignating the first subpart 3 (relat-
ing to other requirements) as subpart 2; and 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
(2) by adding at the end of subpart 2 the fol-
lowing new section: 
‘‘SEC. 2753. COVERAGE FOR INDIVIDUALS PARTICIPATING 
IN APPROVED CANCER CLINICAL TRIALS. 
‘‘The provisions of section 2707 shall apply to health 
insurance coverage offered by a health insurance issuer 
in the individual market in the same manner as they apply 
to health insurance coverage offered by a health insurance 
issuer in connection with a group health plan in the small 
or large group market.’’. 
(c) EFFECTIVE DATES.— 
(1) 
GROUP
HEALTH
PLANS
AND
GROUP 
HEALTH INSURANCE COVERAGE.—Subject to para-
graph (3), the amendments made by subsection (a) 
apply with respect to group health plans for plan 
years beginning on or after January 1, 2007. 
(2) INDIVIDUAL
HEALTH
INSURANCE
COV-
ERAGE.—The amendment made by subsection (b) 
applies with respect to health insurance coverage of-
fered, sold, issued, renewed, in effect, or operated in 
the individual market on or after such date. 
(3) COLLECTIVE BARGAINING EXCEPTION.—In 
the case of a group health plan maintained pursuant 
to 1 or more collective bargaining agreements be-
tween employee representatives and 1 or more em-
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
ployers ratified before the date of enactment of this 
Act, the amendments made subsection (a) shall not 
apply to plan years beginning before the later of— 
(A) the date on which the last collective 
bargaining agreements relating to the plan ter-
minates (determined without regard to any ex-
tension thereof agreed to after the date of en-
actment of this Act), or 
(B) January 1, 2007. 
For purposes of subparagraph (A), any plan amend-
ment made pursuant to a collective bargaining 
agreement relating to the plan which amends the 
plan solely to conform to any requirement added by 
subsection (a) shall not be treated as a termination 
of such collective bargaining agreement. 
(d) COORDINATION OF ADMINISTRATION.—The Sec-
retary of Labor, the Secretary of the Treasury, and the 
Secretary of Health and Human Services shall ensure, 
through the execution of an interagency memorandum of 
understanding among such Secretaries, that— 
(1) regulations, rulings, and interpretations 
issued by such Secretaries relating to the same mat-
ter over which two or more such Secretaries have re-
sponsibility under the provisions of this Act (and the 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
amendments made thereby) are administered so as 
to have the same effect at all times; and 
(2) coordination of policies relating to enforcing 
the same requirements through such Secretaries in 
order to have a coordinated enforcement strategy 
that avoids duplication of enforcement efforts and 
assigns priorities in enforcement. 
(e) STUDY AND REPORT.— 
(1) STUDY.—The Secretary of Health and 
Human Services, jointly with the Secretaries of 
Labor and the Treasury, shall study the impact on 
group health plans and health insurance issuers of 
requiring group health plans and health insurance 
coverage to cover routine patient care costs for indi-
viduals with serious and life threatening diseases 
other than cancer. 
(2) REPORT
TO
CONGRESS.—Not later than 
January 1, 2010, such Secretary shall submit a re-
port to Congress that contains an assessment of— 
(A) any incremental cost to group health 
plans and health insurance issuers resulting 
from the provisions of this section; and 
(B) a projection of expenditures of such 
plans and issuers if coverage of routine patient 
care costs in an approved clinical trial program 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS
were extended to individuals entitled to benefits 
under such plans or health insurance coverage 
who have a diagnosis other than cancer. 
Æ 
VerDate Aug 31 2005 
23:43 Oct 02, 2006
Jkt 049196
PO 00000
Frm 00026
Fmt 6652
Sfmt 6301
E:\BILLS\H6247.IH
H6247
jcorcoran on PRODPC62 with BILLS